General Conditions

3.1 Statement of Expenditures
A statement of all expenditures for the grant, signed by the candidate and the financial officer of each institution, must be received at the CHS's offices within 2 months of the grant terminating.

3.2 Changes in the Use of the Grant
The use of funds for purposes other than stated on the application form must be approved in advance by the CHS.

3.3 Unexpended Balances
The Canadian Hemophilia Society does not permit the carrying forward to a following grant year of any unexpected balance in excess of $5,000. Consideration will be given, however, to prior written requests to carry forward a higher balance.

3.4 Termination of the Grant
Upon termination of the project, any unexpended balance of funds must be returned to the CHS.

3.5 Travel Expenses
A grantee may use $1,500.00 (one thousand, five hundred dollars) annually from the award for the purpose of travel in connection with the grant and, if needed, an additional amount representing one percent (1%) of the annual value of the award.

3.6 Title to Equipment
Title to any equipment obtained with the Canadian Hemophilia Society's funds shall be held by the host institution on the condition that for a 12 month period following termination of grant support at that institution, the CHS may transfer title to another institution. If no action is taken by the CHS during the 12 months, title remains with the host institution. Prior written authorization for the transfer of funds or equipment by a grantee to another institution must be obtained from the CHS.

3.7 Final Report & Abstract
A final report and a short abstract must be submitted within 2 months of the grant terminating.

3.8 Acknowledgement of Support
All publications by grantees should acknowledge the support of the Canadian Hemophilia Society and 2008 and 2009 grantees supported by Bayer HealthCare should also acknowledge its support.

3.9 Proprietary Rights
The CHS must be informed of any commercial exploitation arising from the CHS-supported activity. However, the CHS does not claim proprietary rights to inventions resulting from research supported by its funds. The onus is on the grantee to seek patent protection in collaboration with the university or institute for inventions or developments arising from the CHS-supported research.

3.10 Indirect / Overhead Costs
Grant funds must contribute towards the direct costs of the research program or project for which the funds were awarded. The Institution provides for indirect or overhead costs, such as the costs associated with facilities and basic utilities, the purchase and repair of office equipment, administration fees, insurance for equipment and research vehicles, and basic communication devices such as telephones and fax machines.The funds must be used effectively and economically, and the expenses must be essential for the research supported by the grant.

4.1
An application to the Canadian Hemophilia Society for research support constitutes a pledge on the part of the applicants and their research institutions to respect all the guidelines of the Canadian Hemophilia Society, the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada and the Canadian Council on Animal Care. In the event that these guidelines are not adhered to, the CHS will consider holding funding.

The completed forms required for research involving human subjects and gene therapy in humans, animals and biohazards must be received by the CHS not later than sixty (60) days after the deadline date for the receipt of the application. If approval is not received by the CHS by the end of this period, the application will not be considered.

4.2 Research Involving Human Subjects
Each project in a research proposal involving human subjects and gene therapy in humans must submit the complete designated form, authorized by the local institutional Research Ethics Board in accordance with the TCPS2 document of the Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada,and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010. The Tri-Council Policy Statement is available from the following website: www.pre.ethics.gc.ca/pdf/eng/tcps2/TCPS_2_FINAL_Web.pdf

In addition, all continuing grantees involved in human subjects must submit the complete designated form on an annual basis. Receipt of this form is required for continuation of payment by the CHS of any funds committed for the following year.

4.3 Research on Somatic Cell Gene Therapy in Humans
The Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010 must be adhered to. Any research related to this area must be reviewed by the local institutional Research Ethics Board.

4.4 Care and Use of Experimental Animals
CHS requires that all experiments involving animals be conducted in an ethical way. The facilities for, and the care and use of animals, in any investigation the CHS supports must be in strict accordance with the guidelines set out by the Canadian Council on Animal Care (CCAC) in its publication, Guide to the Care and Use of Experimental Animals (Vol. 1, 1980 and revised in 1993; Vol. 2, 1984), available from:

The Canadian Council on Animal Care
1000 - 151 Slater St.
Ottawa, Ontario Canada K1P 5H3

Each proposal involving animals must have one copy of the designated form, completed and authorized by a local institutional Animal Care Committee, confirming its ethical acceptability (the composition of the committee is set forth in the CCAC Guide). In addition, all continuing grantees involved in research using animals must submit one complete form on an annual basis. Receipt of this form is required for continuation of payment by the CHS of any funds committed for the following year.

4.5 Research Involving Biohazards
Investigators proposing to engage in research involving animal and human pathogens and animal cells are required to comply with the Canadian Institutes of Health Research and Health and Welfare Canada Biosafety Laboratory Guidelines, 3rd Edition – 2004. These guidelines were jointly prepared with the Office of Biosafety of the Laboratory Centre for Disease Control of Health Canada and are available from:

Office of Biosafety
Laboratory Centre for Disease Control
Health Protection Branch
Health Canada
Ottawa, Ontario Canada K1A 0L2
Tel:  613-957-1779 

or at www.phac-aspc.gc.ca/publicat/lbg-ldmbl-04/index-eng.php

These Guidelines cover the following types of research:

a) research involving animal and human pathogens;
b) research involving animal cells in culture;
c) research involving recombinant DNA molecules.

Each proposal involving research proposals covering the areas noted above must have one completed form, authorized by a local institutional committee, confirming that the level of containment implemented by the investigator meets the Canadian Institutes of Health Research's requirements.

In addition, all continuing grantees participating in research involving biohazards must submit a completed form on an annual basis. Receipt of this form is required for continuation of payment by CHS of any funds committed for the following year.

4.6 Research Involving Hazardous Compounds
Researchers are responsible for ensuring that their research conforms with the provincial statutes regarding disposal of chemical wastes. Researchers are also responsible for ensuring that research assistants and laboratory personnel are aware of any hazards posed by materials required for the research, that these personnel are adequately trained in handling and containment of such compounds, and that protective procedures are enforced, in compliance with the Occupational Health and Safety regulations of the province in which work is carried out.

4.7 Research Involving Radioactive Materials
Applicants who will be carrying out research using radioactive materials must be aware of, and comply with, all Atomic Energy Control Board regulations, recommended procedures, and safety precautions governing the use of such materials in Canada. Further information may be obtained from:

Office of Public Information
Atomic Energy Control Board
P.O. Box 1046, Station 'B'
270 Albert Street
Ottawa, Ontario Canada K1P 5S9
Tel:  613-995-5894  Fax: 613-995-5086